The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia (CML), according to a study published in Leukemia.1

The EUTOS registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1 CML in 20 countries and regions of Europe. Median age was 55 years and median observation was 29 months.

Of the 2904 patients included in the analysis, 80% were treated with imatinib in the first-line setting, while 17% received a second generation kinase inhibitor, such as dasatinib and nilotinib.

After 12 months, the complete cytogenetic response rate and major molecular response rate was 57% and 41%, respectively. Those with high EUTOS risk scores were more likely achieve a complete cytogenetic response and a major molecular response later than patients with low EUTOS risk scores.

At 12, 24, and 30 months, the overall survival rates were 97%, 94%, and 92%, respectively. Progression-free survival rates at the same 3 points time points were 95%, 92%, and 90%, respectively.

The investigators also validated the ELTS score for predicting overall survival, as overall survival differed significantly between the 3 risk categories.

The responses and outcomes observed in this population-based study were similar to those reported in clinical trials.

Reference

1. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2 904 CML patients from the EUTOS population based registry. Leukemia. 2016 Aug 29. doi: 10.1038/leu.2016.246.